ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Haematological malignancy,Haematologic neoplasms NEC,Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,Y
2,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2,2,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,Y
2,3,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
3,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
4,1,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
4,2,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
4,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
5,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
5,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
5,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
5,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
6,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
7,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
7,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
7,3,Hypernatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
7,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
8,1,Tubulointerstitial nephritis,Nephritis NEC,Nephropathies,Renal,N
9,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
10,1,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
10,2,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
10,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
11,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
12,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
12,2,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
12,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
13,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,Y
14,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
15,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
16,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
17,1,Infusion site erythema,Infusion site reactions,Administration site reactions,Genrl,N
18,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
18,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
18,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
19,1,Drug effect less than expected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
19,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
19,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
